Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at asco 2020 show durable responses that deepen over time

Tarrytown, n.y. and paris, may 29, 2020 /prnewswire/ -- across all groups combined, complete responses (cr) are now 16%; in the metastatic group with the longest follow-up crs are 20%, nearly tripling with two additional years of follow-up regeneron pharmaceuticals, inc. (nasdaq: regn)...

REGN Ratings Summary

REGN Quant Ranking